Collegium Pharmaceutical (NASDAQ:COLL) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report report published on Friday,Benzinga reports. They currently have a $50.00 price target on the specialty pharmaceutical company’s stock.

A number of other research firms have also weighed in on COLL. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Trading Down 1.3 %

Shares of COLL stock opened at $32.91 on Friday. Collegium Pharmaceutical has a 1-year low of $28.39 and a 1-year high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a 50-day moving average of $30.56 and a two-hundred day moving average of $34.07. The firm has a market cap of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently modified their holdings of the company. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth approximately $757,000. Barclays PLC increased its stake in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after buying an additional 45,291 shares during the period. Squarepoint Ops LLC lifted its holdings in Collegium Pharmaceutical by 194.5% in the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after buying an additional 72,874 shares in the last quarter. Renaissance Technologies LLC boosted its position in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after buying an additional 113,300 shares during the last quarter. Finally, BOKF NA acquired a new stake in shares of Collegium Pharmaceutical during the second quarter valued at about $490,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.